Doxycycline in Acute Traumatic Brain Injury

Damanhour University50 enrolled

Overview

evaluate the impact of Doxycycline on both clinical outcome and blood levels of NSE in patients with TBI.

1. Approval will be obtained from Research Ethics Committee of Faculty of Pharmacy, Damnhour University. 2. All Participants agreed to take part in this clinical research and provide informed consent. for unconscious participants, the informed consent was obtained from their legally authorized representative. 3. Patients with moderate to severe TBI will be enrolled from Tanta university hospitals. 4. Serum samples will be collected for measuring the biomarkers. 5. Our design is randomized, controlled study. 6. All enrolled patients will be divided into 2 groups, Group (1) 25 patients that receive doxycycline 100 mg twice daily, either orally or through a nasogastric tube for 5 days, and group (2) will be 25 patients will receive placebo in addition to the standard treatment. 7. All patients will be followed up during ICU period. 8. Statsicial tests appropriate to the study design will be conducted to evaluate the significance of the results. 9. Measuring outcome: the primary outcome is the change in the serum level of acute brain injury biomarkers. 10. Results, conclusions, discussion and recommendations will be given.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Traumatic Brain Injury

Interventions

Doxycycline 100 MG Oral TabletDRUG

doxycycline 100 mg twice daily, either orally or through a nasogastric tube for 5 day

placeboOTHER

placebo in addition to the standard treatment.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Hospital admission in the first 24 h of injury, 2. 18 to 90 years of age and 3. Both sexes with moderate to severe traumatic brain injury (GCS score ≤ 12). 4. Able to tolerate enteral feeding and drug administration within the first 24 hours of TBI Exclusion Criteria: 1. Hypersensitivity to tetracyclines 2. Pregnant and breast feeding women, 3. History of autoimmune disease. 4. History of receiving chronic steroid treatment and isotretinoin, 5. Pre-existing hepatic (AST, ALT greater than 3 times the upper limit of normal) or renal failure (BUN/ Creatinine 20:1; creatinine \> 2 mg/dL), 6. Known malignancies

Locations (1)

Tanta University Hospital

Tanta, El-Gharbia, Egypt

Outcomes

Primary Outcomes

Neuron specific enolase

levels of NSE

Time frame: 7 days

Glasgow Coma Scale (GCS)

Glasgow Coma Scale (GCS) 15 Points Normal:3 Points Abnormal

Time frame: 7 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.